Patents by Inventor Felix Karim

Felix Karim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190194252
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: March 11, 2019
    Publication date: June 27, 2019
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 10280198
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 7, 2019
    Assignee: KAI PHARMACEUTICALS, INC.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20180022777
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 25, 2018
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 9701712
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: July 11, 2017
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20170114095
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: January 9, 2017
    Publication date: April 27, 2017
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 9567370
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 14, 2017
    Assignee: KAI PHARMACEUTICALS, INC.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20160159860
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: February 8, 2016
    Publication date: June 9, 2016
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 9278995
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: March 8, 2016
    Assignee: KAI PHARMACEUTICALS, INC.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20150175664
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: March 4, 2015
    Publication date: June 25, 2015
    Inventors: FELIX KARIM, AMOS BARUCH, DEREK MACLEAN, KANAD DAS, QUN YIN
  • Patent number: 8999932
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: April 7, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 8987200
    Abstract: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 24, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Gregory Bell, Sarah Walter, Felix Karim
  • Patent number: 8969299
    Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 3, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Gregory Bell
  • Publication number: 20130150301
    Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 13, 2013
    Applicant: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Gregory Bell
  • Patent number: 8377880
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2—X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: February 19, 2013
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek MacLean, Kanad Das, Qun Yin
  • Publication number: 20120178688
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: February 2, 2012
    Publication date: July 12, 2012
    Applicant: KAI PHARMACEUTICALS, INC.
    Inventors: FELIX KARIM, AMOS BARUCH, DEREK MACLEAN, KANAD DAS, QUN YIN
  • Publication number: 20110028394
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: July 29, 2010
    Publication date: February 3, 2011
    Applicant: KAI Pharmaceuticals, Inc.
    Inventors: Felix KARIM, Amos Baruch, Derek MaClean
  • Publication number: 20100311671
    Abstract: Disclosed herein are methods for transdermal delivery of PKC modulatory peptides. Generally, methods comprise the delivery of an isozyme specific PKC peptide modulator through skin that has been microporated, e.g., with an array of microneedles. Such methods may be used to administer therapeutically effective amounts of an isozyme selective PKC peptide inhibitor or activator.
    Type: Application
    Filed: March 25, 2010
    Publication date: December 9, 2010
    Applicant: Kai Pharmaceuticals
    Inventors: Randolph Mellus Johnson, Felix Karim, Lisa Christine Ryner
  • Publication number: 20090023652
    Abstract: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: November 16, 2007
    Publication date: January 22, 2009
    Inventors: Gregory Bell, Sarah Walter, Felix Karim
  • Publication number: 20070269378
    Abstract: Human NADK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morpho-genesis, comprising screening for agents that modulate the activity of NADK are provided.
    Type: Application
    Filed: June 18, 2004
    Publication date: November 22, 2007
    Applicant: EXELIXIS INC.
    Inventors: Gregory Plowman, Felix Karim, Candace Swimmer, Hinrich Habeck, Thomas Koblizek, Stefan Schulte-Merker, Ulrike Eisenmann, Gordon Stott, Torsten Trowe, Andreas Vogel, Joerg Odenthal, Jochen Scheel, Torsten Will, Yinsheng Jin, Lynn Bjerke, Timothy Heuer
  • Publication number: 20070003927
    Abstract: Human MAPK7 genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MAPK7 are provided.
    Type: Application
    Filed: October 22, 2003
    Publication date: January 4, 2007
    Inventors: Gregory Plowman, Felix Karim, Candace Swimmer, Hinrich Habeck, Thomas Koblizek, Stefan Schulte-Merker, Ulrike Langheinrich, Gordon Stott, Torsten Trowe, Andreas Vogel, Joerg Heinrich, Jochen Scheel, Torsten Will, Yisheng Jin, Joanne Adamkewicz